Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 9 estudios
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Oral semaglutide improves glycemic control in type 2 diabetes
Última actualización 5 de julio de 2026
Key finding
The estimated treatment difference (ETD [95% CI]) was -2 (-4, -1) mmol/mol.
This study compared the efficacy and safety of oral semaglutide to sitagliptin in adults with inadequately controlled type 2 diabetes. Results indicated that oral semaglutide led to significantly greater reductions in HbA1c and body weight.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the efficacy and safety of oral semaglutide to sitagliptin in adults with inadequately controlled type 2 diabetes. Results indicated that oral semaglutide led to significantly greater reductions in HbA1c and body weight.
Clinical relevance
These findings are significant for clinicians treating patients with type 2 diabetes, as they highlight the potential of oral semaglutide as a more effective alternative to sitagliptin. Improved glycemic control and weight loss can lead to better overall health outcomes for patients, reducing the risk of diabetes-related complications.
Keep in mind
The study's population may not be representative of all adults with type 2 diabetes. Limited long-term safety data beyond 26 weeks. Potential for bias due to the open-label design.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Linong J, Rikke MA, Stephen CB, et al. Efficacy and safety of oral semaglutide vs sitagliptin in adults with type 2 diabetes inadequately controlled with metformin. Diabetologia. 2024;67(9):1800-1816. doi:10.1007/s00125-024-06133-4
Efectos Principales
Oral semaglutide reduced HbA1c by -2 mmol/mol (p=0.001).
Body weight decreased by -0.9 kg with oral semaglutide (p=0.001).
Oral semaglutide led to a reduction in HbA1c by -8 mmol/mol (p=0.001).
Body weight decreased by -2.3 kg with oral semaglutide (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Sitagliptin and Body weight, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
4
Evidence pairs
564
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and HbA1c
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Guardar evidencia
Relación de evidencia
DPP-4 Inhibitors and HbA1c
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Estudios de apoyo: Basado en 11 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 89
- Very Positive
- ConsistencyScore™
- 100
- consistent
Estudios de apoyo: Basado en 4 estudios
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Oral semaglutide showed a significant reduction in HbA1c levels.
- Participants experienced greater weight loss with oral semaglutide compared to sitagliptin.
- Statistical significance was achieved for both HbA1c and body weight outcomes.
A quién se aplica
- Adults with type 2 diabetes inadequately controlled with metformin.
- Patients seeking alternative oral medications for diabetes management.
Tener en Cuenta
- Results may not generalize to populations outside the study.
- Further research is needed to assess long-term effects.
- The study's design may introduce biases that could affect outcomes.
Entre Líneas
- The study's population may not be representative of all adults with type 2 diabetes.
- Limited long-term safety data beyond 26 weeks.
- Potential for bias due to the open-label design.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and HbA1c.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Estudios de apoyo: Basado en 9 estudios
View evidenceMedications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 87
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Estudios de apoyo: Basado en 11 estudios
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
9 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
9 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
9 results
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide
Intervention: Semaglutide
9 results
All studies measuring Body weight
Outcome: Body weight
9 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 86.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists appears to improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 86.7 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 30 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve HbA1c?
Strong Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect body weight?
Strong Evidence
DPP-4 Inhibitors may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.